Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- VBS.AU
- Price
- 0.08
- Stock movement up
- +- (%)
- Company name
- Vectus Biosystems Ltd
- Exchange
- (AU ,
- Currency
- AUD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 4.05M
- Ent value
- 3.78M
- Price/Sales
- 1.76
- Price/Book
- 2.72
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -8.46%
- 1 year return
- -72.86%
- 3 year return
- -62.05%
- 5 year return
- -31.12%
- 10 year return
- -
Last updated: 2025-04-05
DIVIDENDS
VBS.AU does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.76 |
| Price to Book | 2.72 |
| EV to Sales | 1.64 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 53.25M |
| EPS (TTM) | -0.08 |
| FCF per share (TTM) | -0.06 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 2.30M |
| Gross profit (TTM) | 2.25M |
| Operating income (TTM) | -5.68M |
| Net income (TTM) | -4.30M |
| EPS (TTM) | -0.08 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 97.67% |
| Operating margin (TTM) | -246.81% |
| Profit margin (TTM) | -186.99% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 808.97K |
| Net receivables | 976.23K |
| Total current assets | 1.84M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 964.66K |
| Total assets | 2.03M |
| Accounts payable | 187.06K |
| Short/Current long term debt | 28.93K |
| Total current liabilities | 534.69K |
| Total liabilities | 539.26K |
| Shareholder's equity | 1.49M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -2.84M |
| Capital expenditures (TTM) | 152.90K |
| Free cash flow (TTM) | -3.00M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -289.54% |
| Return on Assets | -212.46% |
| Return on Invested Capital | -284.01% |
| Cash Return on Invested Capital | -197.79% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.08 |
| Daily high | 0.08 |
| Daily low | 0.08 |
| Daily Volume | 0K |
| All-time high | 2.00 |
| 1y analyst estimate | - |
| Beta | 0.91 |
| EPS (TTM) | -0.08 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| VBS.AU | S&P500 | |
| Current price drop from All-time high | -96.20% | -17.56% |
| Highest price drop | -96.25% | -56.47% |
| Date of highest drop | 14 Mar 2025 | 9 Mar 2009 |
| Avg drop from high | -56.47% | -11.07% |
| Avg time to new high | 138 days | 12 days |
| Max time to new high | 875 days | 1805 days |
COMPANY DETAILS
Marketcap
4.05M
Marketcap category
Small-cap
Description
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure; VB4-A32 for the treatment of liver fibrosis; VB4-A79 for the treatment of lung fibrosis; and VB4-P5 for the treatment of renal fibrosis. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops Accugen consisting of AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was incorporated in 2005 and is based in Rosebery, Australia.
Employees
0
Investor relations
-
SEC filings
CEO
Country
Australia
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found